Review
Open access
Modern therapeutic approaches in cholangiocarcinoma: A narrative review of key biomarkers and clinical trials
Augusto Almeida
Joao Manzi
Camila Hoff
H. Kadri
Alan Livingstone
A. Gleisner
Emily Baiyee Toegel
R. Schulick
P. Hoff
Rodrigo Vianna
Phillipe Abreu
Medicine
Abstract
Highlights • Cholangiocarcinoma (CCA) presents a significant clinical challenge with varied subtypes, each requiring tailored treatments.• Early diagnosis of CCA is difficult, leading to poor survival rates, particularly in advanced stages.• Precision medicine is advancing CCA management through targeted therapies based on specific molecular aberrations.• Recent FDA-approved treatments for CCA include therapies targeting HER2, IDH1, FGFR2, and other key biomarkers.